Global Breast Cancer Screening Market was valued at US$ 7.96 billion in 2023 and is projected to surpass the market size of US$ 17.43 billion by 2032 at a CAGR of 9.1% during the forecast period, 2024-2032 | Astute Analytica

The global 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 is on a robust growth trajectory, with its market size expected to increase from 𝐔𝐒$ 𝟕.𝟗𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 to an impressive 𝐔𝐒$ 𝟏𝟕.𝟒𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, at a compound annual growth rate (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟗.𝟏% during the forecast period, 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐. This growth is driven by increasing awareness about early detection, advancements in screening technologies, and rising government initiatives to promote breast cancer awareness globally.

𝐀 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐅𝐢𝐥𝐞@-
https://www.astuteanalytica.com/request-sample/breast-cancer-screening-market

Breast cancer remains one of the most common forms of cancer affecting women, and early detection plays a critical role in improving survival rates. As a result, the demand for breast cancer screening methods, such as mammography, ultrasound, MRI, and other advanced screening tools, continues to surge. The development of more accurate and less invasive diagnostic technologies is also expected to fuel market growth.

Moreover, the increasing prevalence of breast cancer, along with favorable reimbursement policies and expanded healthcare infrastructure in emerging economies, is boosting market demand. North America and Europe are currently leading the market due to higher adoption rates of screening programs, while the Asia-Pacific region is anticipated to exhibit the fastest growth due to rising healthcare investments and increasing public awareness.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

𝐃𝐫𝐢𝐯𝐞𝐫: 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐚𝐧𝐝 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧 𝐨𝐟 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠

Breast cancer is one of the leading causes of cancer-related deaths among women worldwide. However, early detection through regular screening can significantly improve survival rates. The global breast cancer screening market is being driven by the increasing awareness and adoption of screening programs, coupled with advancements in screening technologies.

Today, governments, healthcare organizations, and advocacy groups have been actively promoting breast cancer awareness campaigns, highlighting the benefits of early screening. These initiatives aim to educate women about the significance of regular mammograms and clinical breast examinations, leading to increased participation in screening programs.

Moreover, technological advancements in breast cancer screening have contributed to the breast cancer screening market growth. Traditional screening methods, such as mammography, are being enhanced with digital imaging technologies, including 3D mammography, which provides higher-resolution images and improved accuracy. This has resulted in increased detection rates and reduced false positives, leading to better patient outcomes. Furthermore, the development of minimally invasive techniques, such as breast magnetic resonance imaging (MRI) and automated breast ultrasound (ABUS), has expanded the options available for breast cancer screening, particularly for women with dense breast tissue.

𝐑𝐞𝐚𝐬𝐨𝐧𝐬 𝐭𝐨 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭- https://www.astuteanalytica.com/industry-report/breast-cancer-screening-market

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭

• Siemens Healthcare
• Hologic, Inc
• Myriad Genetics
• Metabolomic Technologies Inc
• Biocrates Lifesciences AG
• A&G Pharmaceuticals
• Provista Diagnostics Inc
• Roche Diagnostics
• Lineage Cell Therapeutics, Inc. (Biotime Inc.)
• General Electric Company
• Quest Diagnostics
• Agendia NV
• Oncocyte Corporation
• Allengers Medical Systems Ltd.
• Other Prominent Players

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

𝐁𝐲 𝐓𝐞𝐬𝐭 𝐓𝐲𝐩

• Imaging Tests
• Ultrasound
• MRI
• Mammogram
o Film mammography
o Digital mammography
o Digital breast tomosynthesis (DBT)
• Genetic Tests
• Other screening Tests (Breast Exam, Thermography, Tissue sampling)

𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫

• Research Labs
• Cancer Institutes
• Diagnostics Centers
• Others

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧

• North America
o The U.S.
o Canada
o Mexico
• Europe
o Western Europe
 The UK
 Germany
 France
 Italy
 Spain
 Rest of Western Europe
o Eastern Europe
 Poland
 Russia
 Rest of Eastern Europe
• Asia Pacific

o China
o India
o Japan
o Australia & New Zealand
o South Korea
o ASEAN
o Rest of Asia Pacific

• 𝐌𝐢𝐝𝐝𝐥𝐞 𝐄𝐚𝐬𝐭 & 𝐀𝐟𝐫𝐢𝐜𝐚 (𝐌𝐄𝐀)

o Saudi Arabia
o South Africa
o UAE
o Rest of MEA

• 𝐒𝐨𝐮𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚

o Argentina
o Brazil
o Rest of South America

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/breast-cancer-screening-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬

𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +18884296757
𝐄𝐦𝐚𝐢𝐥: sales@astuteanalytica.com
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/
LinkedIn | Twitter | YouTube | Facebook

This release was published on openPR.